Search Results - "Tennenberg, A M"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
  2. 2

    Patient stratification in the management of acute bacterial exacerbation of chronic bronchitis: the role of levofloxacin 750 mg by Martinez, F. J, Grossman, R. F, Zadeikis, N, Fisher, A. C, Walker, K, Ambruzs, M. E, Tennenberg, A. M

    Published in The European respiratory journal (01-06-2005)
    “…This is the first prospective clinical trial in which patients with acute bacterial exacerbation of chronic bronchitis have been stratified by degree of…”
    Get full text
    Journal Article
  3. 3

    Multicenter, Postmarketing Assessment of Levofloxacin in the Treatment of Adults with Community-Acquired Pneumonia by Akpunonu, B., Michaelis, J., Uy, C. N., Tennenberg, A. M., Wiesinger, B. A., Karim, R., Marshall, J. Scott, Kahn, J. B.

    Published in Clinical infectious diseases (15-01-2004)
    “…This phase IV, multicenter, open-label trial was designedto provide confirmation of the efficacy and safety of levofloxacin, 500 mg once daily, in a large…”
    Get full text
    Journal Article
  4. 4

    High-Dose, Short-Course Levofloxacin for Community-Acquired Pneumonia: A New Treatment Paradigm by Dunbar, Lala M, Wunderink, Richard G, Habib, Michael P, Smith, Leon G, Tennenberg, Alan M, Khashab, Mohammed M, Wiesinger, Barbara A, Xiang, Jim X, Zadeikis, Neringa, Kahn, James B

    Published in Clinical infectious diseases (15-09-2003)
    “…Levofloxacin demonstrates concentration-dependent bactericidal activity most closely related to the pharmacodynamic parameters of the ratio of area under the…”
    Get full text
    Journal Article
  5. 5

    Varicella Vaccination for Healthcare Workers at a University Hospital: An Analysis of Costs and Benefits by Tennenberg, Alan M., Brassard, Juanita E., Van Lieu, Jaclyn, Drusin, Lewis M.

    “…Objective: To demonstrate the costs and benefits of vaccinating varicella-susceptible healthcare workers at a university hospital with live, attenuated…”
    Get full text
    Journal Article
  6. 6

    Outbreak in a New York City teaching hospital burn center caused by the Iberian epidemic clone of MRSA by Roberts, R B, Tennenberg, A M, Eisner, W, Hargrave, J, Drusin, L M, Yurt, R, Kreiswirth, B N

    “…During an 18-month period in a burn center (January 1995 through June 1996), 109 single-patient MRSA isolates were identified and 102 isolates (94%) were…”
    Get more information
    Journal Article
  7. 7
  8. 8
  9. 9

    Levofloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis: a randomized double-blind multicenter study by Bundrick, William, Heron, Sean P, Ray, Paul, Schiff, William M, Tennenberg, Alan M, Wiesinger, Barbara A, Wright, Pamela A, Wu, Shu-Chen, Zadeikis, Neringa, Kahn, James B

    Published in Urology (Ridgewood, N.J.) (01-09-2003)
    “…To compare the safety and efficacy of levofloxacin with that of ciprofloxacin for the treatment of chronic bacterial prostatitis. In a multicenter,…”
    Get full text
    Journal Article
  10. 10

    Levofloxacin efficacy in the treatment of community-acquired legionellosis by Yu, Victor L, Greenberg, Richard N, Zadeikis, Neringa, Stout, Janet E, Khashab, Mohammed M, Olson, William H, Tennenberg, Alan M

    Published in Chest (01-06-2004)
    “…Although fluoroquinolones possess excellent in vitro activity against Legionella, few large-scale clinical trials have examined their efficacy in the treatment…”
    Get more information
    Journal Article
  11. 11

    Treatment of chronic bacterial prostatitis with levofloxacin and ciprofloxacin lowers serum prostate specific antigen by Schaeffer, Anthony J, Wu, Shu-Chen, Tennenberg, Alan M, Kahn, James B

    Published in The Journal of urology (01-07-2005)
    “…We compared baseline and post-therapy prostate specific antigen (PSA) in patients with chronic bacterial prostatitis who were treated with levofloxacin or…”
    Get more information
    Journal Article
  12. 12

    Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens by Dunbar, Lala M., Khashab, Mohammed M., Kahn, James B., Zadeikis, Neringa, Xiang, Jim X., Tennenberg, Alan M.

    Published in Current medical research and opinion (01-04-2004)
    “…SUMMARY Background: Current recommended durations for treatment of atypical community-acquired pneumonia (CAP) range from 10 to 21 days. However, antibiotics…”
    Get full text
    Journal Article
  13. 13

    A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia by Shorr, Andrew F., Zadeikis, Neringa, Xiang, Jim X., Tennenberg, Alan M., Wes Ely, E.

    Published in Clinical therapeutics (01-08-2005)
    “…Abstract This subgroup analysis sought to determine the efficacy and tolerability of a 5-day regimen of levofloxacin 750 mg/d compared with a 10-day regimen of…”
    Get full text
    Journal Article
  14. 14

    Levofloxacin for Treatment of Ventilator-Associated Pneumonia: A Subgroup Analysis from a Randomized Trial by Shorr, Andrew F., Zadeikis, Neringa, Jackson, William L., Ramage, Anthony S., Wu, Shu-Chen, Tennenberg, Alan M., Kollef, Marin H.

    Published in Clinical infectious diseases (15-02-2005)
    “…Ventilator-associated pneumonia (VAP) remains a significant challenge in critical care. We conducted a secondary analysis of a multicenter, prospective,…”
    Get full text
    Journal Article